I believe that this huge time frame from end of the cd-12 386 patient trail till now has been to collect more data for EUA in several countries. US fda may be further down the list as US covid situation was a lot better 2 months ago than it was a month ago and it’s even worse today. The vaccinations daily rate is going to be down significantly for many reasons very soon. The focus of media will shift to blank % of Americans vaccinated yet covid infections and hospitalizations on the rise like you see in Michigan and many other states. I believe 23 states were all 10% up. Countries like phillipines, Brazil, Canada, and India, covid cases are surging and if they can get a small number of people added into the cd-12 OLE and recalculate the Numbers to show the huge effect leronlimab can do other countries will start approving before the US. I am confident of this because of the Safety profile so many of the other drugs have side effects safety is #1 followed by effectiveness and Leronlimab is the currently most underrated undervalued drug in the world. Soon that will change